Related Experiment Videos
New horizons for autoimmune hyperthyroidism with FcRn blockers
Fearghas Middleton1, Prakash Abraham2
1Specialty Registrar in Endocrinology.
Current Opinion in Endocrinology, Diabetes, and Obesity
|August 6, 2026
Summary
Neonatal Fc receptor (FcRn) blockers show promise for treating autoimmune hyperthyroidism like Graves' disease. Early data suggest efficacy and good tolerability for Batoclimab, though further research is needed.
Area of Science:
- Immunology
- Endocrinology
- Pharmacology
Background:
- Autoimmune hyperthyroidism, including Graves' disease and thyroid eye disease, presents significant challenges in management.
- Advances in neonatal Fc receptor (FcRn) biology have opened avenues for novel immunomodulatory therapies.
Purpose of the Study:
- To review emerging literature on FcRn blockers Batoclimab, Imeroprubart, and Efgartigimod for Graves' disease and thyroid eye disease.
- To evaluate the therapeutic potential and clinical trial progress of these novel agents.
Main Methods:
- Review of preliminary Phase 2 and Phase 3 clinical trial data.
- Analysis of case reports and ongoing clinical trial information.
- Evaluation of FcRn biology in the context of autoimmune thyroid diseases.
Main Results:
- Batoclimab demonstrated rapid normalization of thyroid hormone levels and reduction in anti-TSH receptor antibodies in Graves' disease patients.
- A subset of patients achieved sustained seroconversion with Batoclimab, with one case report showing long-term remission.
- Efgartigimod Phase 3 trials for thyroid eye disease were terminated early due to insufficient efficacy; ongoing trials for Imeroprubart and Batoclimab continue.
Conclusions:
- FcRn blockade represents a promising therapeutic strategy for autoimmune hyperthyroidism.
- Further investigation is required to define the durability, cost-effectiveness, and optimal patient selection for FcRn inhibitor therapies.
Related Concept Videos
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
01:26Atherosclerosis III: Management
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
01:28Drugs Acting on Autonomic Ganglia: Blockers
Ganglionic blockers inhibit autonomic activity by blocking nicotinic receptors in the autonomic ganglia, suppressing impulse transmission. These blockers lack selectivity between sympathetic and parasympathetic ganglia and are ineffective as neuromuscular junction antagonists. They can be categorized into two groups:
01:21Rheumatic Heart Disease III: Medical Management
Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...